Abstract

 CADTH recommends that Skyrizi be reimbursed by public drug plans for the treatment of moderately to severely active Crohn disease (CD) if certain conditions are met.
 Skyrizi should only be covered to treat adult patients with moderately to severely active CD who do not respond to, stop responding to, or who cannot tolerate conventional or biologic therapies.
 Skyrizi should only be reimbursed if prescribed by a physician experienced in the diagnosis and management of CD, if it is not used in combination with other biologics, and if the cost of Skyrizi is reduced so that it does not cost the drug programs more than the least costly biologic therapy. Patients must respond to treatment in the first 12 weeks of starting Skyrizi to continue receiving the drug.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
